Impel Pharmaceuticals

About Impel Pharmaceuticals

Impel Pharmaceuticals, founded in 2008 by John Hoekman and Rodney Ho, is a commercial-stage biopharmaceutical company that was established to develop therapies for central nervous system (CNS) diseases. The company originated from technology Hoekman invented during his PhD in pharmaceutics at the University of Washington. Initially named Impel NeuroPharma, the company rebranded in April 2022 to Impel Pharmaceuticals to reflect its broader focus on various diseases beyond the CNS.

The company's core asset is its proprietary Precision Olfactory Delivery (POD®) technology. This drug delivery platform is designed to administer therapies deep into the vascular-rich upper nasal space, which can allow for rapid and consistent absorption of drugs, potentially mimicking injection-like bioavailability without the need for needles. This method offers an alternative for patients, especially for conditions where oral medications may have limitations due to absorption issues.

Impel's first and primary product is Trudhesa® (dihydroergotamine mesylate) nasal spray, which received FDA approval in September 2021 for the acute treatment of migraine with or without aura in adults. The business model centers on the commercialization of Trudhesa, with revenue generated from its sales. Following its IPO in April 2021, which raised $80 million, the company focused its resources on the commercial launch and expansion of Trudhesa's market presence. Despite a strong launch trajectory, sales did not meet commercial goals, leading to financial difficulties. In February 2023, Impel announced a strategic reprioritization, halting pipeline programs and reducing its workforce by 16% to concentrate on maximizing Trudhesa's growth. However, these measures were insufficient, and after breaching loan covenants, the company filed for Chapter 11 bankruptcy in December 2023. Subsequently, JN Bidco LLC acquired the company and its assets.